Click on link below to view poster/manuscript.

BisEDT, A Novel Small Molecule Drug, Demonstrates Broad Antimicrobial and Anti-Biofilm Activity Against CF Lung Pathogens
North American Cystic Fibrosis Conference 2019, October 31 - November 2, Nashville, TN.

Safety, Tolerability and Efficacy of Adjunctive Treatment with Topically Applied MBN-101 in Subjects with Moderate or Severe Diabetic Foot Infection (DFI): A Phase 1 Randomized, Double blind, Placebo Controlled Study
Symposium on Advanced Wound Care Fall 2019, October 12-14, Las Vegas, NV.

Evaluation of Resistance Development of the Novel Antimicrobial MBN-101 Against Gram-Positive and Gram-Negative Pathogens
ASM Microbe 2019, June 20-24, San Francisco, CA.

Two Phase 1 Clinical Studies Evaluating the Cumulative Irritation and Contact Sensitization on Intact and Abraded Skin of MBN-101, a Novel Antimicrobial Product in Development for Diabetic Foot Ulcer Infection
Symposium on Advanced Wound Care Spring | Wound Healing Society 2019, May 7-11, San Antonio, TX.

Activity Profile of MBN-101: a Novel Antimicrobial Agent with Broad-Spectrum Activity against Bacteria, Including ESKAPE Pathogens
29th European Congress of Clinical Microbiology and Infectious Diseases, April 13-16, 2019, Amsterdam, Netherlands.

Topical Pravibismane as Adjunctive Therapy for Moderate or Severe Diabetic Foot Infections: A Phase 1b Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial
International Wound Journal. 2024;21:e14817. DOI: 10.1111/iwj.14817